Lymphoma Awareness

In a video interview, Jonathon B. Cohen, MD, MS, co-director of the lymphoma program at Winship Cancer Institute of Emory University, discussed:

• promising data on novel therapies in Hodgkin lymphoma presented at ASH 2020, including pembrolizumab (Keytruda, Merck) plus GVD and camidanlumab tesirine (ADC Therapeutics);
• ASH 2020 data from “a particularly exciting year” in non-Hodgkin lymphoma on an anti-CD19 CAR-T therapy in indolent non-Hodgkin lymphoma, LOXO-305, a novel BTK inhibitor, in CLL and mantle cell lymphoma, and CNS prophylaxis in aggressive non-Hodgkin lymphomas;
• research presented at ASH 2020 that will impact clinical practice in the coming year;
• benefits and challenges of a attending a virtual meeting; and
• what he’s looking forward to at the ASH 2021 meeting – “it’s never too early to start looking ahead to what may be coming out later this year.”